Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Isotonic and Hypotonic Intravenous Maintenance Fluids In Term Newborns: Neofluid Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria are:~* Term newborns (\>37 + 0/7 weeks) aged 24 hours to 30 days with a normal baseline serum sodium level between 135-145 mmol/L,with a treatment plan to include IV fluids at \> 50% of maintenance~* Infants not received parenteral fluids in the last 24 hours before participation~* Infants receiving IV fluid administration at 50% to 100% of maintenance~Exclusion Criteria:~* Newborns with diagnoses that required specific fluid tonicity and volumes such as:~  * Severe dehydration presenting with shock~ * Syndrome of inappropriate antidiuretic hormone secretion (SIADH)~ * Renal insufficiency~ * Adrenal insufficiency~ * Diabetes mellitus and diabetes insipidus~ * Hypoxic ischemic encephalopathy~ * Major congenital anomaly~ * Patients receiving diuretic therapy~ * Patients with obvious edema~ * Heart or liver failure, portal hypertension with acid~ * Pre-post operative patients~ * Infants receiving total parenteral nutritional therapy~ * Other: all conditions that require non-standard liquid content and quantities

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: None

Study Arms:
- Isotonic fluid (Type: None): Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~* Dextrose 5% in 0.9% NaCl,~* Intravenous fluid containing NaCl between 131 to 154 mmol/L
- Hypotonic fluid (Type: None): Group, received hypotonic maintenance fluid containing NaCl \< 130 mmol/L such as:~* Dextrose 5 % in 0.02 % NaCl,~* Dextrose 5% in 0.033 % NaCl~* Dextrose 5% in 0.045 % NaCl~* Intravenous fluid containing NaCl \< 130 mmol/L

Based on this trial design, predict the completion outcome and termination type (if applicable).